Department of Ophthalmology, Imperial College Healthcare NHS Trust, London, UK.
Moorfields Eye Hospital NHS Foundation Trust, London, UK.
BMJ Case Rep. 2021 Jun 4;14(6):e240562. doi: 10.1136/bcr-2020-240562.
Postoperative cystoid macular oedema (CMO) is a recognised complication of cataract surgery, occurring in around 1.5% of cases. It is generally managed with topical steroids or non-steroidal anti-inflammatory medications. We present a case of a patient who developed bilateral sequential CMO following bilateral sequential cataract surgery which was non-responsive to topical therapy and worsened following sub-Tenons administration of steroid. The patient took fingolimod for multiple sclerosis both prior to and during the period of cataract surgery which is known to result in the development of macular oedema in some patients. On fingolimod cessation, the oedema resolved over a period of 5 months with good visual recovery. We present this case to inform cataract surgeons of the risk of fingolimod-associated macular oedema in patients undergoing cataract surgery and to inform neurologists of the potential need to adjust treatment for patients undergoing cataract surgery.
术后囊样黄斑水肿(cystoid macular oedema,CMO)是白内障手术后一种公认的并发症,约有 1.5%的病例会发生。它通常通过局部类固醇或非甾体抗炎药物治疗。我们报告了一例患者,该患者在接受双侧序贯白内障手术后发生双侧序贯 CMO,局部治疗无效,在接受 Tenon 下皮质类固醇注射后病情恶化。该患者在白内障手术前后均接受了芬戈莫德治疗多发性硬化症,已知该药物会导致一些患者出现黄斑水肿。停用芬戈莫德后,水肿在 5 个月内消退,视力恢复良好。我们报告这个病例是为了让白内障手术医生了解接受白内障手术的患者使用芬戈莫德相关的黄斑水肿风险,并告知神经科医生对接受白内障手术的患者可能需要调整治疗。